Search Within

Andrew D Seidman

  1. "2020"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Breast Medicine Service (6)
  2. Department of Medicine (6)
  3. Solid Tumor Oncology Division (6)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  5. GSK Faculty (2)
  6. Human Oncology and Pathogenesis Program (2)

More Groups

People
  1. Adrienne Boire (2)
  2. Elena Pentsova (2)
  3. Rachna Malani (2)
  4. Anna Skakodub (1)
  5. Antonio Omuro (1)
  6. Connie Chen (1)

More People

Years
  1. 2020 (6)
Publications
  1. Cancer Research (3)
  2. JNCI Cancer Spectrum (1)
  3. Journal of Neuro-Oncology (1)
  4. Neuro-Oncology (1)
Publishers
  1. American Association for Cancer Research (3)
  2. Oxford University Press (2)
  3. Springer (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Yoga for chemotherapy-induced peripheral neuropathy and fall risk: A randomized controlled trial
    Journal Article

    Bao, T.; Zhi, I.; Baser, R.; Hooper, M.; Chen, C.; Piulson, L.; Li, Q. S.; Galantino, M. L.; Blinder, V.; Robson, M.; more...
    JNCI Cancer Spectrum (2020)

    Fulltext@MSK | Save
  • Clinical outcomes of proton craniospinal irradiation for patients with leptomeningeal carcinomatosis
    Meeting Abstract

    Wijetunga, N. A.; Mohammed, N.; Yamada, Y.; Wolden, S.; Seidman, A.; Yu, H.; Kris, M.; Malani, R.; Pentsova, E.; Boire, A.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
    Journal Article

    Malani, R.; Fleisher, M.; Kumthekar, P.; Lin, X.; Omuro, A.; Groves, M. D.; Lin, N. U.; Melisko, M.; Lassman, A. B.; Jeyapalan, S.; more...
    Journal of Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane
    Meeting Abstract

    Schwartzberg, L.; Asselah, J.; Bondarenko, I.; Chae, Y.; DaCosta, N.; Feng, Y. H.; Izarzugaza, Y.; Lemieux, J.; Liu, M. C.; Marx, G.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane
    Meeting Abstract

    O'Shaughnessy, J.; Piccart, M.; Schwartzberg, L.; Cortes, J.; Harbeck, N.; Im, S. A.; Rugo, H.; Untch, M.; Yardley, D.; Bondarenko, I.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Initial real world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer
    Meeting Abstract

    Carter, G. C.; Sheffield, K. M.; Gossai, A.; Huang, Y. J.; Zhu, Y. E.; Bowman, L.; Smith, E. N.; Mathur, R.; Cohen, A. B.; Baxi, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save